Accessing the Event

Each attendee should have received an email with login information and will receive a reminder email with the same information the morning of the conference.

If you have registered for the event and have not received an email with login information, please check take the following steps:

1. Check your spam/junk folder for the email from Nurse Practitioners of Oregon, NPO@OregonRN.org.
2. Ensure you are checking in the email address you registered for the conference with. Many times the email your registered with or that we have on file is different than your primary email address, so check your other accounts.
3. If you still don't see any email, please contact us at NPO@OregonRN.org.

Conference Information

Join us for the 2021 NPO Pharmacology Conference, held virtually on Saturday, May 22, 2021.

This year's conference will focus on cardiology and the impact of cardiac pharmacology on overall health, including interactions with other medications.

Sessions available:

• Bittersweet Surprise: The New Acceptance of Sugar's Role in Cardiovascular Disease
• Women and Cardiology: Getting to the Heart of the Matter
• Chewing the Fat: Cardiovascular Risk Reduction through Lipid Management
• Impact of Thyroid and Hormone Replacement Therapy on the Cardiovascular System
• Don't Break that Heart! Cardiac Implications of Psychiatric Medications
  
• Anticoagulant Use in Primary Care
• Pediatric Cardiology: Little Bodies, Big Hearts
  

Content Available through June

Featuring LIVE virtual sessions with opportunities to interact with presenters, exhibitors and other attendees!

Each session will be recorded and available to view and earn CE on-demand after the live conference through the end of June. This means every attendee has access to all topics and sessions.

Continuing Education

Participants can earn up to a maximum of 7.5 contact hours (which includes up to 5.71 pharmacotherapeutic contact hours).

Oregon Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Audience

The conference is designed to support the professional practice and learning needs of nurse practitioners, clinical nurse specialists, advanced practice nurses, physician assistants and other interested health care providers by providing a variety of evidence-based educational topics.

If you have any questions or want more information, contact us at NPO@oregonrn.org.

Registration & Fees

Registration is now open and will close Friday, May 21 at noon. 

REGISTRATION RATES:

• $49 for NPO members and students*
  
• $125 for non-members

Schedule of the Day

• 9-10:30 a.m. - Keynote: Bittersweet Surprise: The New Acceptance of Sugar's Role in Cardiovascular Disease
• 10:30-11 a.m. - break
• 11am-12pm - Breakout Session: Women and Cardiology: Getting to the Heart of the Matter
  
• 11am-12pm - Breakout Session: Chewing the Fat: Cardiovascular Risk Reduction through Lipid Management
  
• 11am-12pm - Breakout Session: Impact of Thyroid and Hormone Replacement Therapy on the Cardiovascular System
• 12-12:30pm - break
• 12:30-1:30pm - Breakout Session: Pediatric Cardiology: Little Bodies, Big Hearts
  
• 12:30-1:30pm - Breakout Session: Anticoagulant Use in Primary Care
  
• 12:30-1:30pm - Breakout Session: Don't Break that Heart! Cardiac Implications of Psychiatric Medications
  
• 1:30pm - end of conference

Course Descriptions

Bittersweet Surprise: The New Acceptance of Sugar's Role in Cardiovascular Disease

• Speaker: Dr. David Guarraia, MD, MS
• CE: 1.5 (1.0 pharm)
  
• Description: Metabolic health has largely been ignored by cardiologists treating patients with both heart failure and coronary disease. With new trials identifying blood sugar lowering agents as a means of improving heart health, we are steering a new course in cardiology. Treating blood sugar to improve long-term outcomes in cardiovascular fitness and quality of life. Dr. David Guarraia is the director of cardiac rehabilitation at the St. Charles Heart and Lung Center. Guarraia has an interest in preventive cardiology in an attempt to improve long-term outcomes and quality of life with fewer medications or procedures.
  

Women and Cardiology: Getting to the Heart of the Matter

• Speaker: Jennifer Barr, DNP, FNP-C, CPNP-AC
• CE: 1.0 (0.66 pharm)
• Description: Women and Cardiology: Getting to the Heart of the Matter will explore the data surrounding heart disease as the leading cause of mortality for women in the United States. We'll look at how pregnancy plays a role, including cardiovascular changes that occur throughout pregnancy, the various risk factors associated with cardiac disease during this time, and we'll review the common cardiac medications and their effects on pregnancy. We’ll also review the cardiovascular effects of various types of contraception, and anticoagulation in pregnancy and post-partum. We'll also review how acute MIs differ in women, discussing the standard of care for acute treatment and the guidelines for post-MI medications as they relate to women, and explore sex-based difference such as presentation and post-arrest treatment. Finally, we'll review the unique risks of cardiovascular disease to younger women in particular.

Chewing the Fat: Cardiovascular Risk Reduction through Lipid Management

• Speakers: Jennifer Stanislaw, PharmD, BCACP & Megan Viehmann, PharmD, BCACP
• CE: 1.0 (0.55 pharm)
• Description: The 2019  American College of Cardiology-American Heart Association (ACC-AHA) published guidelines regarding the prevention of cardiovascular disease, expanding on past recommendations for lipid management. This presentation aims to describe the most up to date guidelines for lipid management in specific patient populations in terms of therapeutic and laboratory goals, as well as review the current body of evidence behind the classes of cholesterol lowering medications in reducing cardiovascular outcomes, including mortality assessments. Statin therapy is recommended in patients to aid in both primary and secondary prevention of atherosclerotic cardiovascular disease and have demonstrated reduction of 22% of cardiovascular events, and a 10% reduction in all-cause mortality, while having minimal risk in adverse events. Alternative low-density lipoprotein (LDL) lowering medications such as ezetimibe, bempedoic acid, bile acid sequestrants, PCSK9 inhibitors have also shown varying significant evidence of decreasing LDL levels and can be used alone or in conjunction with statin therapy to achieve lower LDL levels and reduced cardiovascular events, but have limited evidence of preventing cardiovascular related death. Trials involving hypertriglyceridemia treatment with omega-3 fatty acids had yet to show benefit in the reduction of coronary artery disease until the REDUCE-IT trial icosapent ethyl demonstrated evidence of reduced major cardiovascular events by up to 25%. Nearly half of all adults in the United States have established cardiovascular disease, and 47% of Americans have at least one of three key risk factors for heart disease. Cardiovascular risk reduction through lipid management is crucial in reducing the number of complications and cardiovascular related death.

• Speaker: Natalie Gustafson, PharmD
• CE: 1.0 (1.0 pharm)
• Description: The endocrine system plays an important role in maintenance of cardiovascular health. The use of hormone and thyroid replacement therapy in post-menopausal women and aging men can potentially increase or decrease cardiac disease risk, depending on hormones used and delivery methods. For instance, studies have shown that treating hypothyroidism and subclinical hypothyroidism can improve cardiovascular risk factors. Synthetic hormones can have very different impacts on cardiovascular health than natural replacement for women. Oral estrogens can have a positive impact on lipid profiles, endothelial function and possibly insulin sensitivity, yet can have prothrombotic effects, increase C-reactive protein and increase triglycerides which makes their use tricky. Low dose transdermal estrogen therapy has not shown the same increase in stroke and venous thromboembolism risk, so delivery method matters. The type of estrogen used can impact these risk factors as well. Synthetic progestins may negate these positive effects of estrogens, as shown in the WHI and HERS trials. Natural progesterone hasn’t shown this same negative lipid effect as synthetic progestins, though is not as well studied. In 2014, FDA added a cardiovascular warning label to testosterone replacement therapy in men due to reports. However, the trials have not been powered to study cardiovascular events until the TRAVERSE trial that begun in 2018, but its results won’t be published for years. This talk will discuss thyroid, estrogen, progesterone and testosterone replacement in women and men in terms of potential cardiovascular risks and benefits. It will cover the differences between delivery methods and natural vs synthetic hormones.
  

Pediatric Cardiology: Little Bodies, Big Hearts

• Speaker: Jennifer Barr, DNP, FNP-C, CPNP-AC
• CE: 1.0 (0.5 pharm)
• Description: The presentation will start with a brief overview of congenital heart disease, including the incidence and prevalence and advancements in fetal diagnosis. Heart failure in pediatrics will be the first major topic addressed as it is what is most likely to be seen by a pediatrician or primary care provider. Discussion will include what causes heart failure, such as unrepaired cardiac lesions as well as a brief overview of genetic cardiomyopathies and then review pharmacologic interventions including diuresis, ACEi, digoxin, timing of surgical intervention and a focus on encouraging weight gain with fortification. Medical management of pediatric arrhythmias will be the next topic, reviewing the use of beta blockers, amiodarone, sotalol and digoxin. The third area of focus will be anticoagulation in the pediatric patient including ASA, Lovenox and coumadin, which is most likely to be used after repair or replacement of a cardiac valve.
  

Anticoagulant Use in Primary Care

• Speaker: Capella Crowfoot Lapham, FNP, DNP
• CE: 1.0 (1.0 pharm)
• Description: This session reviews updated guidelines based on emerging evidence on use of anticoagulants and antiplatelet agents for conditions commonly treated in primary care such as DVT, atrial fibrillation, and cardiovascular conditions.
  

Don't Break that Heart! Cardiac Implications of Psychiatric Medications

• Speaker: Susan Swift, PMHNP-BC
• CE: 1.0 (1.0 pharm)
• Description: The cardiovascular side effects of antidepressants, antipsychotics, mood stabilizers, and stimulants will be discussed including mild and serious adverse effects such as increased heart rate, hypotension, hypertension, prolonged bleeding, QTc prolongation, clozapine-induced myocarditis, and cardiomyopathy, with suggestions on the management of these side effects.

Other Information

MEMBER TYPES:

• *NPO Member Rate is for members of ONA/NPO or members of other state nurses associations that are affiliated with the American Nurses Association. Proof of membership in other state nurses associations required.  
• Non-Member Rate is for NPs and CNSs who are not a member of NPO, physicians, physician assistants, and all allied health professionals.
• NP Student Rate is for students who are currently enrolled in an NP program. Proof of enrollment will be required. 

CANCELLATIONS:

Registration may be canceled by written request only. Cancellations must be received on or before May 15, 2021. No refunds will be given after May 15, 2021. Written cancellations should be mailed to: NPO, 18765 SW Boones Ferry Road, Suite 200, Tualatin, OR 97062, or email: NPO@oregonrn.org.